Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.
The U.S. Food and Drug Administration (FDA) has agreed to increase the maximum Palynziq (pegvaliase-pqpz) dose allowed for treating adults with phenylketonuria (PKU), BioMarin announced. While the maximum dose previously ... Read more
A slow-release formulation of large neutral amino acids (LNAAs) improves adherence to treatment and quality of life in adults with phenylketonuria (PKU), a study suggests. The study, “The Impact of a Slow-Release ... Read more
PTC Therapeutics will be advancing CNSA-001 (sepiapterin) — an investigational oral therapy for phenylketonuria (PKU) and other metabolic disorders — because the company is acquiring the original developer of the treatment, Censa Pharmaceuticals. ... Read more
The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still lacking ... Read more